ARIA-EAACI statement on Asthma and COVID-19

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F21%3A73601147" target="_blank" >RIV/61989592:15110/21:73601147 - isvavai.cz</a>

Výsledek na webu

<a href="https://pubmed.ncbi.nlm.nih.gov/32588922/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/32588922/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/all.14471" target="_blank" >10.1111/all.14471</a>

Jazyk výsledku

angličtina

Název v původním jazyce

ARIA-EAACI statement on Asthma and COVID-19

Popis výsledku v původním jazyce

A novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), named by the International Committee on Taxonomy of Viruses (ICTV),1 has recently emerged and caused an infectious disease. This disease is referred to as the “coronavirus disease 2019” (COVID‐19) by the World Health Organization (WHO).2 The US Centers for Disease Control and Prevention (CDC) have proposed that “People with moderate to severe asthma may be at higher risk of getting very sick from COVID‐19. COVID‐19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack and possibly lead to pneumonia and acute respiratory disease.” (May 24, 2020). (https://www.cdc.gov/coronavirus/2019‐ncov/need‐extra‐precautions/asthma.html) On the other hand, in the UK, NICE proposes rapid guidelines for severe asthma (https://www.guidelines.co.uk/covid‐19‐rapid‐guideline‐severe‐asthma/455275.article). An ARIA‐EAACI statement has been devised to make recommendations on asthma, and not necessarily on severe asthma, based on a consensus from its members. It is difficult in many studies to clearly assess the prevalence of asthma on COVID‐19 since most patients are older adults and probably have multimorbidities. Most studies do not clarify whether asthmatic patients with COVID‐19 have isolated asthma or asthma as a multimorbidity, particularly in the context of hypertension, obesity and diabetes. In particular, obesity is a significant risk factor for COVID‐19 and its severity,3 and may be intertwined with asthma.

Název v anglickém jazyce

ARIA-EAACI statement on Asthma and COVID-19

Popis výsledku anglicky

A novel strain of human coronaviruses, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), named by the International Committee on Taxonomy of Viruses (ICTV),1 has recently emerged and caused an infectious disease. This disease is referred to as the “coronavirus disease 2019” (COVID‐19) by the World Health Organization (WHO).2 The US Centers for Disease Control and Prevention (CDC) have proposed that “People with moderate to severe asthma may be at higher risk of getting very sick from COVID‐19. COVID‐19 can affect your respiratory tract (nose, throat, lungs), cause an asthma attack and possibly lead to pneumonia and acute respiratory disease.” (May 24, 2020). (https://www.cdc.gov/coronavirus/2019‐ncov/need‐extra‐precautions/asthma.html) On the other hand, in the UK, NICE proposes rapid guidelines for severe asthma (https://www.guidelines.co.uk/covid‐19‐rapid‐guideline‐severe‐asthma/455275.article). An ARIA‐EAACI statement has been devised to make recommendations on asthma, and not necessarily on severe asthma, based on a consensus from its members. It is difficult in many studies to clearly assess the prevalence of asthma on COVID‐19 since most patients are older adults and probably have multimorbidities. Most studies do not clarify whether asthmatic patients with COVID‐19 have isolated asthma or asthma as a multimorbidity, particularly in the context of hypertension, obesity and diabetes. In particular, obesity is a significant risk factor for COVID‐19 and its severity,3 and may be intertwined with asthma.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ALLERGY

ISSN

0105-4538

e-ISSN

—

Svazek periodika

76

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

689-697

Kód UT WoS článku

000571269800001

EID výsledku v databázi Scopus

2-s2.0-85091138547